# VERU INC. (VERU) · Edgar & Edgarette company card

> Veru (VERU) grew revenue 3.6% in FY2024 to $17 million, operating margin -214% against a -3.8% median for pharmaceutical preparations, equity 53.5% of assets, and dividend per share up 1 year running. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 863894 · fiscal year ended 2024-09-30 · 5 audited years read · [page](https://www.pops4.com/boards/company/VERU) · [JSON](https://www.pops4.com/boards/company/VERU.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $17M |
| Revenue growth, 1 year | 3.6% |
| Revenue growth per year | -20.6% |
| Operating margin | -214.2% (prior year -575.5%) |
| Net margin | -223.9% |
| Operating cash flow | −$22M |
| Capital spending | $158,322 |
| Free cash flow | −$22M |
| Cash | $25M |
| Long-term debt | — |
| Total assets | $60M |
| Total equity | $32M |
| Equity ÷ assets | 53.5% |
| Return on equity | -117.0% |
| Dividend per share | $0.21 |
| Dividend years rising | 1 |

## Readings, computed from those figures

- Altman Z: -16.17 (distress zone)
- Piotroski F: 5 of 9 (middling)
- Beneish M: -3.55 (below the −1.78 line)
- Health Harbor boat: Old boat · three warning signs · slow and jumpy: growing slower than its size class, with revenue that swings more; operating cash flow was negative; revenue is hard to predict: its 80% range is ±75%
- Cash Compass: Fading · slow and jumpy, lagging its peers

## Edgarette's reading

Exposure: revenue $16.9M (FY2024). Experience: revenue up 3.6% on the year, down 20.6% a year over 4 years; operating margin -214.2%, up from -575.5%. Soundness: equity 53.5% of assets, return on equity -117.0%, dividend per share up 1 year running. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $5.4M and $36.9M next year (method v4.1: its own 6-year record of growth weighed at 63% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $4.7M to $42.2M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -214.2% against a -3.8% median; growth 3.6% against 13.7%.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2026-03-13 ([filing](https://www.sec.gov/Archives/edgar/data/863894/000143774926008216/0001437749-26-008216-index.htm))

## Recent filings

- 8-K · filed 2026-09-08 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/863894/000119312526384430/0001193125-26-384430-index.htm)
- 10-Q · filed 2026-08-10 · [filing](https://www.sec.gov/Archives/edgar/data/863894/000143774926026664/0001437749-26-026664-index.htm)
- 8-K · filed 2026-08-10 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/863894/000119312526341187/0001193125-26-341187-index.htm)
- 8-K · filed 2026-07-02 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/863894/000119312526294507/0001193125-26-294507-index.htm)
- 8-K · filed 2026-06-04 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/863894/000143774926019478/0001437749-26-019478-index.htm)
- 10-Q · filed 2026-05-13 · [filing](https://www.sec.gov/Archives/edgar/data/863894/000143774926016557/0001437749-26-016557-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0000863894.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=863894

## Cite

POPS4, Edgar & Edgarette: VERU INC. (VERU) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/VERU. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Its latest audited year is FY2025, which reports no revenue; the revenue figures and the range here are from FY2024, its last year with revenue on record. Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.